This review discusses the rationale behind recommending immunopharmacological guidance of long-term
therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical
outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional
anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual
patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects.
Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual
patients would also help industry to develop more effective and safer TNF-α inhibitors” .
Keywords: Antibodies to anti TNF, anti TNF treatment, Crohn’s disease, optimisation, trough levels of anti TNF, ulcerative
Rights & PermissionsPrintExport